IceCure Medical (NASDAQ:ICCM) and DocGo (NASDAQ:DCGO) Head to Head Survey

IceCure Medical (NASDAQ:ICCM) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares IceCure Medical and DocGo”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38 million	2.11	-$15.06 million	($7.21)	-0.35
DocGo	$322.20 million	0.17	-$182.40 million	($1.91)	-0.29

IceCure Medical has higher earnings, but lower revenue than DocGo. IceCure Medical is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for IceCure Medical and DocGo, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1	1	3	0	2.40
DocGo	1	2	3	0	2.33

IceCure Medical presently has a consensus price target of $62.70, indicating a potential upside of 2,368.50%. DocGo has a consensus price target of $2.38, indicating a potential upside of 327.39%. Given IceCure Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe IceCure Medical is more favorable than DocGo.

Risk & Volatility

IceCure Medical has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, DocGo has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.

Profitability

This table compares IceCure Medical and DocGo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
DocGo	-62.23%	-44.09%	-29.14%

Summary

DocGo beats IceCure Medical on 9 of the 13 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About DocGo

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.